Details

Autor(en) / Beteiligte

• Zhao, Min
• Mantel, Irmela
• Gelize, Emmanuelle
• Li, Xinxin
• Xie, Xiaoyue
• Arboleda, Alejandro
• Seminel, Marie
• Levy-Boukris, Rinath
• Dernigoghossian, Marilyn
• Prunotto, Andrea
• Andrieu-Soler, Charlotte
• Rivolta, Carlo
• Canonica, Jérémie
• Naud, Marie-Christine
• Lechner, Sebastian
• Farman, Nicolette
• Bravo-Osuna, Irene
• Herrero-Vanrell, Rocio
• Jaisser, Frederic
• Behar-Cohen, Francine

Titel

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Ist Teil von

• Nature communications, 2019-01, Vol.10 (1), p.369-369, Article 369

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory to intraocular anti-VEGF injections. Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition of the MR pathway or endothelial-specific deletion of MR inhibits CNV through VEGF-independent mechanisms, in part through upregulation of the extracellular matrix protein decorin. Intravitreal injections of spironolactone-loaded microspheres and systemic delivery lead to similar reductions in CNV. Together, our work suggests MR inhibition as a novel therapeutic option for wet AMD patients unresponsive to anti-VEGF drugs.